Moleculin Biotech (MBRX) Competitors $1.67 -0.14 (-7.73%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MBRX vs. LVTX, ENLV, LSB, AKTX, SNTI, INKT, CMMB, EQ, CLDI, and MTEXShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include LAVA Therapeutics (LVTX), Enlivex Therapeutics (ENLV), Lakeshore Biopharma (LSB), Akari Therapeutics (AKTX), Senti Biosciences (SNTI), MiNK Therapeutics (INKT), Chemomab Therapeutics (CMMB), Equillium (EQ), Calidi Biotherapeutics (CLDI), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. LAVA Therapeutics Enlivex Therapeutics Lakeshore Biopharma Akari Therapeutics Senti Biosciences MiNK Therapeutics Chemomab Therapeutics Equillium Calidi Biotherapeutics Mannatech Moleculin Biotech (NASDAQ:MBRX) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations. Is MBRX or LVTX more profitable? Moleculin Biotech has a net margin of 0.00% compared to LAVA Therapeutics' net margin of -228.02%. LAVA Therapeutics' return on equity of -62.22% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -157.44% -97.16% LAVA Therapeutics -228.02%-62.22%-29.37% Does the media favor MBRX or LVTX? In the previous week, LAVA Therapeutics had 3 more articles in the media than Moleculin Biotech. MarketBeat recorded 5 mentions for LAVA Therapeutics and 2 mentions for Moleculin Biotech. LAVA Therapeutics' average media sentiment score of 0.24 beat Moleculin Biotech's score of 0.00 indicating that LAVA Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LAVA Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend MBRX or LVTX? Moleculin Biotech presently has a consensus price target of $24.00, indicating a potential upside of 1,337.13%. LAVA Therapeutics has a consensus price target of $3.33, indicating a potential upside of 223.62%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Moleculin Biotech is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00LAVA Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the MarketBeat Community favor MBRX or LVTX? Moleculin Biotech received 203 more outperform votes than LAVA Therapeutics when rated by MarketBeat users. However, 69.44% of users gave LAVA Therapeutics an outperform vote while only 50.44% of users gave Moleculin Biotech an outperform vote. CompanyUnderperformOutperformMoleculin BiotechOutperform Votes22850.44% Underperform Votes22449.56% LAVA TherapeuticsOutperform Votes2569.44% Underperform Votes1130.56% Do insiders & institutionals believe in MBRX or LVTX? 15.5% of Moleculin Biotech shares are held by institutional investors. 7.1% of Moleculin Biotech shares are held by company insiders. Comparatively, 0.8% of LAVA Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, MBRX or LVTX? Moleculin Biotech has higher earnings, but lower revenue than LAVA Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$29.77MN/AN/ALAVA Therapeutics$7.35M3.55-$41.97M-$1.03-1.00 Which has more volatility & risk, MBRX or LVTX? Moleculin Biotech has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. SummaryMoleculin Biotech beats LAVA Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.33M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.1317.20Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.145.094.784.78Net Income-$29.77M$151.83M$120.31M$225.60M7 Day Performance-28.02%-2.14%-1.92%-1.23%1 Month Performance-38.83%-4.56%13.65%0.46%1 Year Performance-83.63%8.87%28.34%15.24% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech2.3563 of 5 stars$1.67-7.7%$24.00+1,337.1%-83.4%$5.33MN/A0.0020News CoverageLVTXLAVA Therapeutics3.0636 of 5 stars$1.02-8.1%$4.67+357.7%-31.8%$25.85M$7.35M-1.0860Analyst ForecastGap DownENLVEnlivex Therapeutics2.316 of 5 stars$1.18-1.7%$9.50+705.1%-45.6%$25.26MN/A0.0070LSBLakeshore Biopharma0.5039 of 5 stars$2.69+8.0%N/AN/A$25.04M$80.82M0.00773News CoverageGap UpAKTXAkari TherapeuticsN/A$0.97-0.3%N/A-68.2%$24.02MN/A0.009Analyst ForecastGap DownHigh Trading VolumeSNTISenti Biosciences2.3348 of 5 stars$5.23-6.1%$10.00+91.2%-9.6%$24M$2.56M-0.334News CoverageGap UpINKTMiNK Therapeutics2.2354 of 5 stars$0.60-2.6%$6.50+983.3%-48.4%$23.73MN/A-1.4930Gap UpCMMBChemomab Therapeutics3.3163 of 5 stars$1.65+4.4%$7.33+344.4%+242.9%$23.69MN/A-1.5820Positive NewsEQEquillium2.7452 of 5 stars$0.66-6.9%$5.00+662.2%-7.7%$23.24M$45.91M-5.0440Gap DownCLDICalidi Biotherapeutics2.341 of 5 stars$1.75-5.4%$16.67+852.4%N/A$22.89M$50,000.000.0041News CoverageGap DownMTEXMannatech0.2131 of 5 stars$11.85+13.6%N/A+56.8%$22.28M$131.96M-13.90250Analyst ForecastGap Up Related Companies and Tools Related Companies LVTX Competitors ENLV Competitors LSB Competitors AKTX Competitors SNTI Competitors INKT Competitors CMMB Competitors EQ Competitors CLDI Competitors MTEX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MBRX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
